|
| 產(chǎn)地 | 進口、國產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號 | CS10807 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
| CAS編號 | |
| 抗體名 | Anti-Phospho-p63 (Ser160/Ser162) |
| 克隆性 | |
| 靶點 | 詳見說明書 |
| 適應(yīng)物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標識物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated Synthesised phosphopeptide derived from human p63 around the phosphorylation site of Ser160/Ser162 |
抗體的生物素化標記實驗要點：
1. 磷酸化P63抑制基因抗體品牌 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當則影響標記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件；
3.用NHSB量過量也是不利的,抗原的結(jié)合位點可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；
5.當游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點時,或位于酶的催化位點時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團,如羰基、氨基、巰基、異咪唑基及*基,也可與糖基共價結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；
8.在細胞的熒光標記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細胞可導(dǎo)致高本底。
產(chǎn)品訂購信息：
英文名稱 Anti-Phospho-p63 (Ser160/Ser162)
中文名稱 磷酸化P63抑制基因抗體品牌
別 名 p63 (phospho S160/162); p63 (phospho Ser160/Ser162); p-p63 (Ser160/Ser162); AIS; Amplified in squamous cell carcinoma; B(p51A); B(p51B); p63 Alpha; Chronic ulcerative stomatitis protein; CUSP; DN p63 alpha 1; DNp63; EEC3; Keratinocyte transcription factor; Keratinocyte transcription factor KET; KET; LMS; NBP; OFC8; p40; p51; P51/P63; p53 like transcription factor; p53 related protein; p53-related protein p63; p53CP; p63; P73; p73H; p73L; RHS; SHFM4; TP53CP; TP53L; TP63; TP73; TP73L; Transformation related protein 63; Trp53rp1; Trp63; Tumor protein 63; tumor protein 63 kDa with strong homology to p53; Tumor protein p53-competing protein; Tumor protein p53-like; tumor protein p63; Tumor protein p73; tumor protein p73-like; P63_HUMAN.
濃 度 1mg/1ml
規(guī) 格 0.1ml/100μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Dog, Pig, Horse, Sheep
產(chǎn)品類型 一抗 磷酸化抗體
研究領(lǐng)域 細胞生物 免疫學(xué) 轉(zhuǎn)錄調(diào)節(jié)因子
蛋白分子量 predicted molecular weight: 77kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated Synthesised phosphopeptide derived from human p63 around the phosphorylation site of Ser160/Ser162
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
磷酸化P63抑制基因抗體品牌 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 This gene encodes a member of the p53 family of transcription factors. An animal model, p63 -/- mice, has been useful in defining the role this protein plays in the development and maintenance of stratified epithelial tissues. p63 -/- mice have several developmental defects which include the lack of limbs and other tissues, such as teeth and mammary glands, which develop as a result of interactions between mesenchyme and epithelium. Mutations in this gene are associated with ectodermal dysplasia, and cleft lip/palate syndrome 3 (EEC3); split-hand/foot malformation 4 (SHFM4); ankyloblepharon-ectodermal defects-cleft lip/palate; ADULT syndrome (acro-dermato-ungual-lacrimal-tooth); limb-mammary syndrome; Rap-Hodgkin syndrome (RHS); and orofacial cleft 8. Both alternative splicing and the use of alternative promoters results in multiple transcript variants encoding different proteins. Many transcripts encoding different proteins have been reported but the biological validity and the full-length nature of these variants have not been determined. [provided by RefSeq, Jul 2008].
Function : Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge.
Subunit : Binds DNA as a homotetramer. Isoform composition of the tetramer may determine transactivation activity. Isoforms Alpha and Gamma interact with HIPK2. Interacts with SSRP1, leading to stimulate coactivator activity. Isoform 1 and isoform 2 interact with WWP1. Interacts with PDS5A. Isoform 5 (via activation domain) interacts with NOC2L.
Subcellular Location : Nucleus.
Post-translational modifications : May be sumoylated.
Ubiquitinated. Polyubiquitination involves WWP1 and leads to proteasomal degradation of this protein.
DISEASE : Acro-dermato-ungual-lacrimal-tooth syndrome (ADULT syndrome) [MIM:103285]: A form of ectodermal dysplasia. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. ADULT syndrome involves ectrodactyly, syndactyly, finger- and toenail dysplasia, hypoplastic breasts and nipples, intensive freckling, lacrimal duct atresia, frontal alopecia, primary hypodontiaand loss of permanent teeth. ADULT syndrome differs significantly from EEC3 syndrome by the absence of facial clefting. Note=The disease is caused by mutations affecting the gene represented in this entry.
Ankyloblepharon-ectodermal defects-cleft lip/palate (AEC) [MIM:106260]: An autosomal dominant condition characterized by congenital ectodermal dysplasia with coarse, wiry, sparse hair, dystrophic nails, slight hypohidrosis, scalp infections, ankyloblepharon filiform adnatum, maxillary hypoplasia, hypodontia and cleft lip/palate. Note=The disease is caused by mutations affecting the gene represented in this entry.
Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 (EEC3) [MIM:604292]: A form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. It is an autosomal dominant syndrome characterized by ectrodactyly of hands and feet, ectodermal dysplasia and facial clefting. Note=The disease is caused by mutations affecting the gene represented in this entry.
Split-hand/foot malformation 4 (SHFM4) [MIM:605289]: A limb malformation involving the central rays of the autopod and presenting with syndactyly, median clefts of the hands and feet, and aplasia and/or hypoplasia of the phalanges, metacarpals, and metatarsals. Some patients have been found to have mental retardation, ectodermal and craniofacial findings, and orofacial clefting. Note=The disease is caused by mutations affecting the gene represented in this entry.
Limb-mammary syndrome (LMS) [MIM:603543]: Characterized by ectrodactyly, cleft palate and mammary-gland abnormalities. Note=The disease is caused by mutations affecting the gene represented in this entry.
Note=Defects in TP63 are a cause of cervical, colon, head and neck, lung and
Ectodermal dysplasia, Rapp-Hodgkin type (EDRH) [MIM:129400]: A form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Characterized by the combination of anhidrotic ectodermal dysplasia, cleft lip, and cleft palate. The clinical syndrome is comprised of a characteristic facies (narrow nose and small mouth), wiry, slow-growing, and uncombable hair, sparse eyelashes and eyebrows, obstructed lacrimal puncta/epiphora, bilateral stenosis of external auditory canals, microsomia, hypodontia, cone-shaped incisors, enamel hypoplasia, dystrophic nails, and cleft lip/cleft palate. Note=The disease is caused by mutations affecting the gene represented in this entry.
Non-syndromic orofacial cleft 8 (OFC8) [MIM:129400]: A birth defect consisting of cleft lips with or without cleft palate. Cleft lips are associated with cleft palate in two-third of cases. A cleft lip can occur on one or both sides and range in severity from a simple notch in the upper lip to a complete opening in the lip extending into the floor of the nostril and involving the upper gum. Note=The disease is caused by mutations affecting the gene represented in this entry.
Similarity : Belongs to the p53 family.
Contains 1 SAM (sterile alpha motif) domain.
Database links : UniProtKB/Swiss-Prot: Q9H3D4.1
P63—也是抑制因子之一.p63基因是基因p53的同源性基因，主要表達上皮組織的基底細胞或復(fù)層上皮細胞，如皮膚、食道、宮頸外口、扁桃體、膀胱等，和、乳腺腺樣結(jié)構(gòu)的基層細胞。
抗體的鑒定：
1）磷酸化P63抑制基因抗體品牌 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴散試驗,酶聯(lián)免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴散試驗來鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力?？贵w的特異性高,它的識別能力就強。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。
Anti-Sema4C/FITC 熒光素標記臂板蛋白4C抗體IgGMulti-class antibodies規(guī)格： 0.2ml
MMP-9(matrix metalloproteinase 9) 基質(zhì)金屬蛋白酶-9(抗原)Multi-class antibodies規(guī)格： 0.5mg
粘蛋白-1/上皮膜抗原抗體 Anti-mucin-1/Muc-1/CD227 antigen 0.1ml
SOX6 英文名稱： 核轉(zhuǎn)錄因子SOX6抗體 0.2ml
Phospho-FRAP1 (Ser2448) 英文名稱： 磷酸化雷帕霉素靶蛋白抗體 0.1ml
Rhesus antibody Rh Phospho-Paxillin (Tyr118) 磷酸化樁蛋白Paxillin抗體 規(guī)格 0.1ml
MMP-9(matrix metalloproteinase 9) 基質(zhì)金屬蛋白酶-9(抗原)Multi-class antibodies規(guī)格： 0.5mg
Anti-phospho-IkB beta (Ser23)/FITC 熒光素標記磷酸化KB抑制蛋白β抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Anti-Pokemon/FITC 熒光素標記兔抗蒙抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh ARH/LDL receptor adaptor protein 受體銜接蛋白抗體 規(guī)格 0.2ml
Rabbit Anti-Mink IgG/PE PE標記的兔抗水貂IgG 0.1ml
GABPB2 英文名稱： GA結(jié)合蛋白轉(zhuǎn)錄因子β/GABP-β1/GABP-β2抗體 0.2ml
Rhesus antibody Rh Rabbit Anti-Mink IgG/PE-Cy5.5 PE-Cy5.5標記的兔抗水貂IgG 規(guī)格 0.1ml
Anti-Pokemon/FITC 熒光素標記兔抗蒙抗體IgGMulti-class antibodies規(guī)格： 0.2ml
PI3K 大鼠磷脂酰肌醇激酶Multi-class antibodies規(guī)格： 48T
Anti-EPEC/E.coli 腸致病性大腸桿菌抗體Multi-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh mucin 5B/Muc5B 粘蛋白-5B抗體 規(guī)格 0.2ml
PF-3(Human platelet factor 3) ELISA Kit 人血小板因子3 96T
SIM2 英文名稱： 轉(zhuǎn)錄因子蛋白SIM2抗體 0.2ml
CSFV 英文名稱： 豬瘟病毒抗體 0.1ml
Anti-EPEC/E.coli 腸致病性大腸桿菌抗體Multi-class antibodies規(guī)格： 0.2ml
L-酪酸營養(yǎng)瓊脂基礎(chǔ)28382250g用于蠟樣芽孢桿菌的L-酪酸分解試驗。
Dermasel 瓊脂 (CM0539) Oxoid incubation media Dermasel 瓊脂 (CM0539) Oxoid
酸土脂環(huán)芽孢桿菌 牛奶中青霉素的檢測;用于益生菌類食品 支/瓶
PresenceAbsenceBroth
Mueller-HintonAgar
抗生素5號250g用于兩性霉素B檢定菌種培養(yǎng)
玫瑰紅瓊脂 250(g) incubation media 玫瑰紅瓊脂 250(g)
沙氏液體培養(yǎng)基 250g 用于真菌的增菌培養(yǎng)，還用于一次性使用衛(wèi)生用品真菌定性檢測
細菌瓊脂粉250培養(yǎng)基原材料，培養(yǎng)基凝固劑incubationmedia細菌瓊脂粉250培養(yǎng)基原材料，培養(yǎng)基凝固劑
WILKINS-CHALGREN瓊脂 250g 用于厭氧菌的分離培養(yǎng)
磷酸化P63抑制基因抗體品牌 明膠培養(yǎng)基(營養(yǎng)明膠) 規(guī)格： 250g 用途： 供鑒別測定細菌液化明膠用
營養(yǎng)瓊脂培養(yǎng)基NA 規(guī)格： 250g 用途： 供細菌總數(shù)測定、保存菌種及純培養(yǎng)用，也可用于消毒效果測定。(GB)
伊紅美藍瓊脂培養(yǎng)基(EMB) 規(guī)格： 250g 用途： 用于分離腸道致病菌特別是大腸菌群和糞大腸菌群。(GB、美國FDA、USP、ISO)
乳糖膽鹽培養(yǎng)基（含中和劑） 規(guī)格： 250g 用途： 用于化妝品糞大腸菌群的測定。(化妝品衛(wèi)生規(guī)范)
|
|
|
|
|
